GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...